KRAS and non-small cell lung carcinoma: For instance, though gain-of-function KRAS mutations are associated with poor prognosis in NSCLC (12), there are emerging data suggesting that KRAS-mutated NSCLC tumors are preferentially sensitive to ICIs (46).